Evidence map›Paper›PMID 38250345›Full record

ArticleACS omega2024

Structural Optimization and Biological Evaluation of Isoxazolo[5,4

Nika Strašek Benedik, Ana Dolšak, Urban Švajger, Izidor Sosič, Stanislav Gobec, Matej Sova

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nika Strašek BenedikFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.ORCID https://orcid.org/0009-0008-8149-970X
Ana DolšakFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.
Urban ŠvajgerFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.
Izidor SosičFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.ORCID https://orcid.org/0000-0002-3370-4587
Stanislav GobecFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.ORCID https://orcid.org/0000-0002-9678-3083
Matej SovaFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.ORCID https://orcid.org/0000-0002-8977-3450
University of Ljubljana · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLRs) are components of innate immunity that play a crucial role in several diseases, including chronic inflammatory and infectious diseases, autoimmune diseases, and cancer. In particular, TLR7 has been identified as a key player in the innate immune response against viral infections and small-molecule TLR7 agonists have shown potential for vaccine therapy, for treatment of asthma and allergies, and as anticancer drugs. Inspired by our previous discovery of selective TLR7 agonists, our goal was to develop and introduce a new chemotype of TLR7 agonists by replacing the quinazoline ring with a new heterocycle isoxazolo[5,4

Identifiers

PMID38250345
PMCPMC10795023
OpenAlexW4390590869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.